244 related articles for article (PubMed ID: 10529077)
1. Cardiovascular advantages of a third generation calcium antagonist. Symposium on lacidipine. Foreword.
Zanchetti A
Drugs; 1999; 57 Suppl 1():2 p preceding 1. PubMed ID: 10529077
[No Abstract] [Full Text] [Related]
2. [Drug information about lercanidipine. A new dihydropyridine calcium antagonist for the treatment of arterial hypertension].
Christensen KL
Ugeskr Laeger; 2005 Jan; 167(2):153-5. PubMed ID: 15697124
[No Abstract] [Full Text] [Related]
3. [Hypertension in type 2 diabetic patients. Calcium antagonist supports the left heart].
MMW Fortschr Med; 2001 Jun; 143(25):58. PubMed ID: 11469003
[No Abstract] [Full Text] [Related]
4. Calcium channel blocker.
Li CJ; Shi ZD
Clin Ther; 2010 Feb; 32(2):396; author reply 397. PubMed ID: 20206797
[No Abstract] [Full Text] [Related]
5. [Also for problem cases; successful first line therapy].
MMW Fortschr Med; 2005 Feb; 147(5):47. PubMed ID: 15766030
[No Abstract] [Full Text] [Related]
6. Lacidipine. Aponil, Caldine, GR 43659, GR 43659X, GX 1048, Lacimen, Lacipil, Lacirex, Midotens, Motens, SN 305, Viapres.
Drugs R D; 2002; 3(5):324-30. PubMed ID: 12455153
[No Abstract] [Full Text] [Related]
7. Safety profile of lacidipine: a review of clinical data.
Endersby CA; Brown EG; Perelman MS
J Cardiovasc Pharmacol; 1991; 17 Suppl 4():S45-7. PubMed ID: 1726006
[TBL] [Abstract][Full Text] [Related]
8. [Third generation of calcium antagonists: focus on lacidipine].
Sidorenko BA; Stetsenko TM; Preobrazhenskiĭ DV; Savchenko MV; Soplevenko AV; Shabaeva EN
Kardiologiia; 2002; 42(12):81-90. PubMed ID: 12494025
[TBL] [Abstract][Full Text] [Related]
9. [Dihydropyridines for treatment of arterial hypertension].
Bareza N; Gasser S; Toferer E; Scheer E; Pruthi D; Gasser R
Pharm Unserer Zeit; 2005; 34(5):388-91. PubMed ID: 16180361
[No Abstract] [Full Text] [Related]
10. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
Meier P; Burnier M
Rev Med Suisse; 2006 Sep; 2(78):2047-50, 2052-3. PubMed ID: 17019840
[TBL] [Abstract][Full Text] [Related]
11. Clinical advantages of lipophilic dihydropyridines.
Mancia G; Omboni S; Zanchetti A
Blood Press Suppl; 1998; 2():23-6. PubMed ID: 9850439
[TBL] [Abstract][Full Text] [Related]
12. Role of dihydropyridinic calcium channel blockers in the management of hypertension.
Coca A; Mazón P; Aranda P; Redón J; Divisón JA; Martínez J; Calvo C; Galcerán JM; Barrios V; Roca-Cusachs I Coll A
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):91-105. PubMed ID: 23259449
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of lacidipine: update from a clinical trials database.
Lindholm LH; Tcherdakoff P; Zanchetti A
Drugs; 1999; 57 Suppl 1():27-9. PubMed ID: 10529080
[No Abstract] [Full Text] [Related]
14. [Antihypertensive therapy. Can a calcium antagonist stop arteriosclerosis?].
MMW Fortschr Med; 2001 May; 143(22):53. PubMed ID: 11460409
[No Abstract] [Full Text] [Related]
15. [Dihydropyridines are not the only antihypertensives. Calcium blockers in the therapy of elderly hypertensive patients].
Fortschr Med Suppl; 1989; 71():1-18. PubMed ID: 2635677
[No Abstract] [Full Text] [Related]
16. Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine?
Burnier M; Pruijm M; Wuerzner G
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):981-7. PubMed ID: 19619074
[TBL] [Abstract][Full Text] [Related]
17. Watanidipine. AE 0047, Calbren, GJ 0956, Vatanidipine.
Drugs R D; 2002; 3(5):331-6. PubMed ID: 12455154
[No Abstract] [Full Text] [Related]
18. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release.
Takahara A
Cardiovasc Ther; 2009; 27(2):124-39. PubMed ID: 19426250
[TBL] [Abstract][Full Text] [Related]
19. The impact of lacidipine, a novel dihydropyridine calcium antagonist, on carbohydrate and lipid metabolism.
Spieker C; Zidek W
J Cardiovasc Pharmacol; 1995; 25 Suppl 3():S23-6. PubMed ID: 8852541
[TBL] [Abstract][Full Text] [Related]
20. [New calcium antagonist. Therapy of hypertension becomes more tolerable].
MMW Fortschr Med; 2001 Oct; 143(40):56-7. PubMed ID: 11692852
[No Abstract] [Full Text] [Related]
[Next] [New Search]
